NCT06656559尚未招募2 期
Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma: A Prospective, Single-Arm, Single-Center Phase II Clinical Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 30
- 主要终点
- Overall Survival
研究概览
简要总结
The sequential treatment strategy of ERCP-RFA combined with envafolimab and surufatinib proposed in this study aims to maximally inhibit the progression of unresectable biliary tract tumors through the combined application of multiple therapeutic modalities. ERCP-RFA, as a local treatment, first reduces the tumor burden and alleviates biliary obstruction through physical ablation. Subsequently, Envafolimab enables the body to more effectively identify and attack the remaining tumor cells by activating the immune system. Finally, Surufatinib as a targeted drug, further controls the growth and spread of tumors by inhibiting tumor angiogenesis and cell proliferation. The potential advantage of this combined treatment lies in the complementary effects of different therapeutic modalities.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign written informed consent.;
- •18-79 years of age (at the time of signing the informed consent);
- •Patients with confirmed diagnosis of biliary tract tumors by histopathologic examination;
- •Patients have received no previous local treatment or any systemic treatment, and have been considered unsuitable for radical therapies
- •Patients assessed by the investigator as unsuitable for or refusing chemotherapy
- •At least one measurable lesion (≥10 mm long diameter on CT scan for tumor lesions and ≥15 mm short diameter on CT scan for lymph node lesions according to RECIST 1.1 criteria);
- •ECOG score: 0-1;
- •Expected survival ≥ 12 weeks;
- •Vital organ function in accordance with the following requirements (excluding any blood components and cell growth factors within 14 days): 1) blood routine: neutrophils ≥ 1.5 × 10^9/L platelet count ≥ 60 × 10^9/L hemoglobin ≥ 90 g/L; 2) liver and kidney function: serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 50 ml/min (Cockcroft-Gault formula); total bilirubin (TBIL) ≤ 1.5 times ULN; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≤ 2.5 ULN (≤ 5ULN if liver function abnormalities are due to liver metastases); urine protein < 2 +; if urine protein ≥ 2 +,24-hour urine protein must show protein ≤ 1g;
- •Normal coagulation, no active bleeding and thrombosis disease 1) international normalized ratio INR ≤ 1.5 × ULN; 2) partial thromboplastin time APTT ≤ 1.5 × ULN; 3) prothrombin time PT ≤ 1.5 × ULN;
- •Non-surgically sterilized or female patients of childbearing age who need to use a medically recognized contraceptive (such as an intrauterine device, contraceptive pills or condom) during study treatment and within 3 months after the end of study treatment; non-surgically sterilized female patients of childbearing age must have a negative serum or urine HCG test within 7 days before study enrollment; and must be non-lactating; non-surgically sterilized or male patients of childbearing age who need to agree to use a medically recognized contraceptive during study treatment and within 3 months after the end of study treatment with their spouses.
- •Willing and able to be followed up until death or end of study or study termination.
排除标准
- •History of other malignancies (except basal cell carcinoma of the skin and/or carcinoma in situ of the cervix after radical surgery).
- •Previous treatment with other immune checkpoints; the subject known to have a prior allergy to macromolecular protein preparations;
- •Presence of any active autoimmune disease or history of autoimmune disease in the subject;
- •Subjects who are on immunosuppressive, or systemic, or absorbable topical hormone therapy for immunosuppression (dose >10mg/day prednisone or other equipotent hormone) and who continue to be on it within 2 weeks prior to enrollment.
- •Subjects with uncontrolled pleural effusion, pericardial effusion, or ascites that require repeated drainage;
- •Patients with poorly controlled cardiac clinical symptoms or diseases such as: (1) NYHA2 or higher heart failure, (2) unstable angina pectoris, (3) myocardial infarction within 1 year, (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;
- •Subjects with active infection or unexplained fever >38.5 degrees Celsius during screening and prior to the first dose (if the subject had fever due to the tumor, as determined by the investigator, he could be enrolled);
- •Previous and current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc.;
- •Subjects with congenital or acquired immune deficiency (e.g., HIV-infected individuals)
- •Subjects who have had a live bacterial vaccine or live attenuated vaccine vaccine within 4 weeks prior to the first dose of study treatment.
- •Subject has a known history of psychiatric drug abuse, alcoholism, or drug abuse;
- •Patients who cannot be administered orally
- •The subject had received treatment with traditional Chinese medicine within 2 weeks before the first treatment
- •ECOG score: ≥2
- •Patients with any other diseases, dysfunction caused by metastatic lesions, or suspected disease found by physical examination, indicating possible contraindications to the use of the investigational drug or putting the patients at high risk of treatment-related complications.
研究组 & 干预措施
Envafolimab and Surufatinib
Experimental
干预措施: Envafolimab and Surufatinib (Drug)
结局指标
主要结局
Overall Survival
时间窗: up to 12 months
Defined as the time from the start of study treatment to death due to any cause
次要结局
- Disease Control Rate(up to 12 months)
- Progression-Free Survival(up to 12 months)
- Overall Response Rate(up to 12 months)
- Adverse events was evaluated during received protocol therapy according to the NCI Common Terminology Criteria for NCI- CTCAE 5.0.(up to 12 months)
研究者
相似试验
尚未招募
不适用
PROceeding With Advanced Techniques in Case of Distal Malignant Biliary Obstruction and Difficult Biliary Cannulation comparEd With Therapeutic-EUS: the PROMETHEUS TrialMalignant Biliary ObstructionNCT06550973Istituto Clinico Humanitas220
Unknown
不适用
Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal DisordersAmpullary CancerDuodenal CancerBile Duct CancerBile Duct DisordersObstructive JaundicePancreatic Disorders (Noncancerous)Barrett's EsophagusColorectal CancerGallstonesGastric MalignanciesPediatric GastroenterologyPancreatic PseudocystsAcute and Chronic PancreatitisPancreatic CancerBile LeakBiliary StricturesPancreatic DivisumBiliary and Pancreatic StonesCholedocholithiasisEsophageal CancerCholangiocarcinomaCholangitisRecurrent PancreatitisNCT01438385Weill Medical College of Cornell University12,000
招募中
不适用
Efficacy of ERCP in the Diagnosis and Treatment of Idiopathic Recurrent Acute PancreatitisRecurrent Acute PancreatitisNCT06364397Changhai Hospital158
尚未招募
不适用
Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde CholangiopancreatographyCholedocholithiasisCholedocholithiasis With Acute CholangitisSclerosing CholangitisPancreatic Cancer ResectablePancreatic Cancer Non-resectableCholangiocarcinomaBiliary FistulaNCT06670547Germans Trias i Pujol Hospital3,000
终止
2 期
IV Ibuprofen for the Prevention of Post-ERCP PancreatitisPost-ERCP Acute PancreatitisNCT02241512University of Texas Southwestern Medical Center69